Gliolan® is approved in 34 countries and used in over 40,000 neurosurgeries
Strong Clinical Data led to EU Approval: in late 2007, the European Medicines Agency (EMA) granted marketing authorization for Gliolan® for the visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV).
Costas G. Hadjipanayis, M.D., Ph.D. at Mount Sinai in New York is sponsoring a multicenter experiential Gliolan® clinical trial. The goal is to include up to 100 centers across the United States. NXDC is providing regulatory and logistical support to this exciting opportunity for patients in the U.S. to benefit from Gliolan® use prior to FDA approval. If you would like to learn more about this clinical trial click here.
To receive additional information about getting trained to use Gliolan® please fill out the form below: